P
P. S. Almond
Researcher at University of Minnesota
Publications - 25
Citations - 1624
P. S. Almond is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 14, co-authored 25 publications receiving 1599 citations. Previous affiliations of P. S. Almond include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Risk factors for chronic rejection in renal allograft recipients.
P. S. Almond,A. J. Matas,K. J. Gillingham,David L. Dunn,William D. Payne,Paul F. Gores,Rainer W.G. Gruessner,J. S. Najarian +7 more
TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Journal ArticleDOI
Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: A multivariate analysis
Christoph Troppmann,K. J. Gillingham,Enrico Benedetti,P. S. Almond,Rainer W.G. Gruessner,J. S. Najarian,Arthur J. Matas +6 more
TL;DR: The impact of delayed graft function on outcome after cadaver renal transplantation has been controversial, but most authors fail to control for the presence or absence of rejection.
Journal ArticleDOI
Long-term quality of life after kidney transplantation in childhood.
P. Morel,P. S. Almond,Arthur J. Matas,K. J. Gillingham,C. Chau,Annie Brown,Clifford E. Kashtan,S. M. Mauer,Blanche M. Chavers,Thomas E. Nevins +9 more
TL;DR: It is concluded that transplanted children with long-term graft function have a favorable social and professional outcome and quality of life seems excellent.
Journal ArticleDOI
Risk factors for second renal allografts immunosuppressed with cyclosporine.
P. S. Almond,Arthur J. Matas,Kristen J. Gillingham,Christoph Troppmann,William D. Payne,David L. Dunn,David E.R. Sutherland,John S. Najarian +7 more
TL;DR: Retransplantation in patients who are immunosuppressed with CsA, especially those who lost their primary graft to either rejection greater than or equal to 6 months posttransplant or nonimmunologic causes; who receive living related grafts; and who have a peak PRA of 1-20 are supported.